¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Cell biochemistry and function."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • differentiated cell
    ºÐÈ­¼¼Æ÷
  • diffuse large B-cell lymphoma
    ±¤¹üÀ§Å«B¼¼Æ÷¸²ÇÁÁ¾
  • diploid cell
    µÎ¹è¼öü¼¼Æ÷
  • diploid cell line
    µÎ¹è¼öü¼¼Æ÷°è, À̹èü¼¼Æ÷°è
  • diploid cell strain
    µÎ¹è¼öü¼¼Æ÷ÁÖ
  • decoy cell
    µðÄÚÀ̼¼Æ÷
  • effector cell
    ÀÛµ¿¼¼Æ÷
  • egg cell
    ³­¼¼Æ÷, ¾Ë¼¼Æ÷
  • embryonic stem cell
    ¹è¾ÆÁٱ⼼Æ÷
  • endothelial cell
    ³»ÇǼ¼Æ÷
  • enterochromaffine cell
    âÀÚÅ©·Òģȭ¼¼Æ÷, ÀåÅ©·Òģȭ¼¼Æ÷
  • enteropathy-type T-cell lymphoma
    À庴ÁõÇüT¼¼Æ÷¸²ÇÁÁ¾
  • eosinophilic cell
    È£»ê¼¼Æ÷
  • ependymal cell
    ³ú½Ç¸·¼¼Æ÷
  • epidermal cell
    Ç¥ÇǼ¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • cone cell
    ¿ø»Ô¼¼Æ÷
  • cone cell layer
    ¿ø»Ô¼¼Æ÷Ãþ
  • connective tissue cell
    °áÇÕÁ¶Á÷¼¼Æ÷
  • continuous cell line
    ¹«ÇÑÁõ½Ä¼º¼¼Æ÷ÁÖ, ¿¬¼Ó°è´ë¼¼Æ÷ÁÖ
  • continuous cell separator
    ¿¬¼Ó¼¼Æ÷ºÐ¸®±â
  • contractile fiber cell
    ¼öÃ༶À¯¼¼Æ÷
  • cover cell
    µ¤°³¼¼Æ÷
  • crenated cell
    Åé´ÏÀûÇ÷±¸
  • crypt cell
    âÀÚ»ù¼¼Æ÷
  • cuboidal cell
    ÀԹ漼Æ÷, ÁÖ»çÀ§¼¼Æ÷
  • cylindrical cell
    (¢¡columnar cell) ¿øÁÖ¼¼Æ÷
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹é
  • dark cell
    ¾îµÒ¼¼Æ÷
  • daughter cell
    µþ¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • aneuploid cell
    À̼ö¼º¼¼Æ÷
  • anitschkow cell
    ¾Æ´ÏÄ¡ÄÚ¿ì¼¼Æ÷(¡­á¬øà)
  • annular elastotic giant cell granuloma
    ȯ»ó ź·Â ¼¶À¯¼º °Å´ë¼¼Æ÷ À°¾ÆÁ¾
  • anoxic cell
    ¹«»ê¼Ò¼¼Æ÷
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • insect bites and stings
    °ïÃæ±³»ó(ÍàõùÎáß¿)¹× ÀÚ»ó(í©ß¿)
  • intake and output record
    ¼·Ãë¿Í ¹è¼³·® ±â·Ï.
  • international commission on radiation units and me
    asurements (ICRU)
  • jejunal and ileal veins <³ª> venae jejunales et ilei
    °øÈ¸ÀåÁ¤¸Æ(°øÈ¸ÀåÁ¤¸Æ).
  • jejunal and ileal veins ³ª venae jejunales et ilei
    °øÈ¸ÀåÁ¤¸Æ(Íöüß ð¡Øæ).
  • kidney ureter and bladder =KUB
    ½Å-´¢°ü-¹æ±¤ ´Ü¼øÃÔ¿µ
  • lateral cord and associated anterior cornual syndrome
    Ãø»èµ¿ÃøÀü°¢ÁõÈıº (ö°ßãÔÒö°îñÊÇñøý¦ÏØ).
  • law for control of poisonous and powerful agents
    µ¶±Ø¹°Ãëü¹ý(ËÄË»ËŅ̬̃ ËÑ).
  • law of weights and measures
    °è·®¹ý(Ë­ËâËÑ).
  • layer of rods and cones
    °£Ã¼ÃßüÃþ
  • layer of rods and cones =bacillary l.
    °£»óüÃß»óüÃþ( ßÒô÷õÞßÒô÷öµ) .
  • left and right handedness
    Á¿ì¼ÕÀâÀÌ(ñ§éÓ~).
  • leukocyte,migration and chemotaxis
    À̵¿(ì¹ÔÑ)°úÈ­ÇÐÃßÇ⼺(ûùùÊõÙú¾àõ)
  • levator muscle of upper lip and ala of nose =musc
    »ó¼øºñÀͰűÙ
  • levator muscle of upper lip and ala of nose<³ª> musculus levator labii superioris alaeque nasi
    »ó¼øºñÀÍ(ß¾âîÞ¬ìÏ)°Å ±Ù.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Flagellated epithelial cell
    Æí¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Æí¸ð»óÇǼ¼Æ÷
  • Squamous epithelial cell
    ÆíÆò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò»óÇǼ¼Æ÷
  • Squamous cell
    ÆíÆò¼¼Æ÷
    [¿¾ ¿ë¾î] ÆíÆò¼¼Æ÷
  • Phagocytic synovial cell
    Æ÷½ÄÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·½Ä¼¼Æ÷
  • Superficial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÀåÇ¥¸é¼¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥Ãþ»óÇǼ¼Æ÷
  • Surface epithelial cell
    Ç¥¸é»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Ç¥¸é»óÇǼ¼Æ÷
  • Superficial epithelial cell
    Ç¥¸é¼¼Æ÷
    [¿¾ ¿ë¾î] õ»óÇǼ¼Æ÷
  • Pyramidal cell
    ÇǶó¹Ô¼¼Æ÷
    [¿¾ ¿ë¾î] Ãßü¼¼Æ÷
  • Mesangial cell
    Ç÷°ü»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü°£¼¼Æ÷
  • Intravascular giant cell
    Ç÷°ü¼Ó°Å´ë¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷°ü³»°Å´ë¿µ¾ç¸·¼¼Æ÷
  • [Pluripotential hemopoietic stem cell]
    Ç÷±¸¸ð¼¼Æ÷
    [¿¾ ¿ë¾î] Ç÷±¸¸ð¼¼Æ÷
  • Plasma cell
    ÇüÁú¼¼Æ÷
    [¿¾ ¿ë¾î] ÇüÁú¼¼Æ÷
  • Paneth cell
    È£»ê¼º°ú¸³¼¼Æ÷
    [¿¾ ¿ë¾î] »êÈ£¼º°ú¸³¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
DTF detector transfer function
EFDA expanded function dental assistant
ESF electron scatter function; electrosurgical filter; erythropoietic stimulating factor
ETF electron-transferring flavoprotein; eustachian tube function
exp expansion; expectorant; experiment, experimental; expiration, expired; exponential function; exposur...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
EPSDT Early and Periodic Screening Diagnosis and Treatment
SUPPORT Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment
HNSCC Head and Neck Squamous Cell Carcinoma
HNSCC Head and neck squamous cell cancers
HTLV-I/II Human T cell lymphotropic virus types I and II
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • capsule cell
    ÇǸ· ¼¼Æ÷, À§¼º ¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷
  • caveolated cell
    ¼ÒÆ÷¿ò ¼¼Æ÷
    ÈçÈ÷ º¼ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¼ÒÀå, ´ëÀå, À§ µîÀÇ ¿ò°ú À¶¸ð¿¡¼­ º¼ ¼ö ÀÖ´Ù. ²À´ë±âº¸´Ù ¹Ù´Ú ºÎºÐÀÌ ³ÐÀ¸¸ç ²À´ë±â¿¡´Â ¹Ì¼¼ À¶¸ð°¡ Àִµ¥ ±× ¼Ó¿¡´Â ¼¼»ç ´Ù¹ßÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼¼»ç ´Ù¹ß »çÀÌ¿¡ ¼¼Æ÷¸·ÀÌ ÇÔÀÔµÈ ¼Ò¿òµéÀÌ ÀÖ´Ù.
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò
    1. »ýü Á¶Á÷ÀÇ ±âº» ´ÜÀ§. Çö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÑ À¯±âü¸¦ ±¸¼ºÇÏ´Â ´Ù¾çÇÑ ¿øÇüÁú µ¢¾î¸® Áß ÇÑ °¡Áö. °¢ ¼¼Æ÷´Â ¼¼Æ÷¸·, ¿øÇüÁú, ÇÙ, ´Ù¾çÇÑ ºÀÀÔü¸¦ °¡Áö°í ÀÖ´Ù. °¢ ¼¼Æ÷ Á¾·ù´Â °¢°¢ÀÇ ´ë»ç ¿ä±¸, ÀÛ¿ë, Åõ°úµµ, ´Ù¸¥ ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â ´É·Â, Àç»ý»ê¼º°ú ¼ö¸íÀ» °¡Áø »ì¾Æ ÀÖ´Â ´ÜÀ§ÀÌ´Ù. 2. »ý¹°ÀÇ ¸öÀ» ±¸¼ºÇÏ´Â ÃÖ¼ÒÀÇ ´ÜÀ§. ¸¹Àº »ý¹°Àº ´Ù¼öÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¼¼Æ÷ »ý¹°À̶ó°í ÇÏÁö¸¸, ¾î¶² Á¾¿¡¼­´Â ±× ÀÚü°¡ ÇϳªÀÇ ¼¼Æ÷·Î µÇ¾î Àֱ⠶§¹®¿¡ ´Ü¼¼Æ÷»ý¹°À̶ó ÇÑ´Ù. ¼¼±Õ, ±ÔÁ¶, ¹Ý´Þ¸», Ŭ·Î·¼¶ó¿Í °°Àº °£´ÜÇÑ Á¶·ù, ¾Æ¸Þ¹Ù, ¤½Å¹ú·¹¿Í °°Àº ¿ø»ýµ¿¹° µîÀº ´Ü¼¼Æ÷»ý¹°ÀÌ´Ù. º¸Åë µ¿¹°ÀÇ ³­ÀÚ´Â ¹ß»ý Ãʱ⿡´Â ´Ü¼¼Æ÷ÀÌÁö¸¸, °ð ºÐ¿­ÇÏ¿© ´Ù¼¼Æ÷·Î µÈ´Ù. ´«À¸·Î º¸ÀÌ´Â °Í¿¡´Â ¹ß»ý ÃʱâÀÇ µ¿¹°ÀÇ ³­ÀÚ, ½Å°æ¼¼Æ÷
  • cell adhesion molecular deficiency
    ¼¼Æ÷ À¯Âø ºÐÀÚ °áÇÌ
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
  • cell color ratio
    Ç÷±¸»ö¼Òºñ, ÀûÇ÷±¸ »ö¼Òºñ
  • cell count
    ¼¼Æ÷ ¼ö
    ´ÜÀ§ ºÎÇÇ´ç Æ÷ÇԵǾî ÀÖ´Â ¼¼Æ÷ ¼ö·Î¼­ º¸Åë ´ÜÀ§ ºÎÇÇ´ç Ç÷¾×¿¡ Æ÷ÇԵǾî ÀÖ´Â ÀûÇ÷±¸¿Í/ȤÀº ¹éÇ÷±¸¸¦ ¸»ÇÑ´Ù.
  • cell culture biocompatibility test
    ¼¼Æ÷ ¹è¾ç »ýü ÀûÇÕ¼º °Ë»ç¹ý
  • cell cycle-non specific
    ¼¼Æ÷ Áֱ⠺ñƯÀ̼º Á¦Á¦
  • cell death
    ¼¼Æ÷»ç
    ¼¼Æ÷°¡ Á׾´Â °úÁ¤¿¡¼­ »ýü ÀÛ¿ëÀÌ ¼¼Æ÷ ¼öÁØ¿¡¼­ Áß´ÜµÈ ÁöÁ¡. ¼¼Æ÷»ç´Â Á¶Á÷À̳ª Àå±â¸¦ Àå±â ÀÌ½Ä °ø¿©Ã¼·Î »ç¿ëÇÏ´Â °Í¿¡ ¾Õ¼­ ÀϾ´Ù.
  • cell differentiation
    ¼¼Æ÷ ºÐÈ­
    ¼¼Æ÷µéÀÌ Á¶Á÷ÀÇ ´Ù¾çÇÑ ±âº» ¼¼Æ÷ ´ÜÀ§·Î ¼ºÀåÇÏ´Â °Í. »óÇǼ¼Æ÷, ½Å°æ¼¼Æ÷
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
post and core technique Use of a metal casting, usually with a post in the pulp or root canal, designed to support and retain an artificial crown.
(12 Dec 1998)
haematologic, gastrointestinal, and renal agents A collective grouping for agents that act on the haematopoietic, gastrointestinal, and renal systems.
(12 Dec 1998)
haematoxylin and eosin stain <technique> Probably the most generally useful of all staining methods for tissues; nuclei are stained a deep blue-black with haematoxylin, and cytoplasm is stained pink after counterstaining with eosin, usually in water.
(05 Mar 2000)
half and half nail Division of the nail by a transverse line into a proximal dull white part and a distal pink or brown part; seen in uraemia.
(05 Mar 2000)
hand-and-foot syndrome <syndrome> Recurrent painful swelling of the hands and feet occurring in infants and young children with sickle cell anaemia.
Synonym: sickle cell dactylitis.
(05 Mar 2000)
H and D curve Sensitometric curve of radiographic film, a plot of the film density versus the logarithm of the relative exposure.
Synonym: H and D curve, Hunter and Driffield curve.
(05 Mar 2000)
hand-foot-and-mouth disease <infectious disease> Hand, foot and mouth disease is a mild, highly infectious viral disease of children, characterised by vesicular lesions in the mouth and on the hands and feet. Occurs most often in young children (under 3) and is transmitted via close contact.
Outbreaks occur most often in the spring. Usually begins as a throat infection (pharyngitis) that later includes a rash (blisters) on the hands, feet and diaper area. Blisters may also appear on the throat and in the mouth.
Other features include anorexia, headache and fever. The illness is typically self-limited, lasting 5-7 days. There is no specific treatment other than general supportive care.
An exanthematous eruption of small, pearl-gray vesicles of the fingers, toes, palms, and soles, accompanied by often painful vesicles and ulceration of the buccal mucous membrane and the tongue and by slight fever; the disease lasts 4 to 7 days, and is usually caused by Coxsackie virus type A-16, but other types have been identified.
(05 Mar 2000)
hand-foot-and-mouth disease virus The virus causing hand-foot-and-mouth disease; chiefly type A16 but also types A4, A5, A7, A9, or A10 Entervirus coxsackievirus.
(05 Mar 2000)
Harris and Ray test A test for vitamin C in the urine; a microtitration test of the urine against a known amount of 0.05% aqueous solution of the dye 2,6-dichloroindophenol in 10% acetic acid (usually 0.05 ml of dye is used, roughly equivalent to 0.025 mg of ascorbic acid).
Synonym: Harris test.
(05 Mar 2000)
head and neck neoplasms Neoplasms of the head and neck.
(12 Dec 1998)
saccule and utricle Two membranous sacs within the vestibule of the inner ear. The smaller, the saccule, lies near the opening of the scala vestibuli. The larger, the utricle, is in the superoposterior part of the vestibule. Both receive filaments from the acoustic nerve.
(12 Dec 1998)
health and human services See HHS.
(12 Dec 1998)
health care economics and organizations The economic aspects of health care, its planning, and delivery. It includes government agencies and organizations in the private sector.
(12 Dec 1998)
health care facilities, manpower, and services The services provided in the delivery of health care, associated facilities in health care, and attendant manpower required or available.
(12 Dec 1998)
health care quality, access, and evaluation The concept concerned with all aspects of the quality, accessibility, and appraisal of health care and health care delivery.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • short and
    =AMPERSAND
  • skull and crossbones
    (Á×À½ÀÇ »ó¡ÀÎ)ÇØ°ñ ¹Ø¿¡ ´ëÅð°ñÀ» ¿­½ÊÀڷΠ¦ÁöÀº ±×¸²(ÇØÀû±â,µ¶¾àÀÇ Ç¥Áö)
  • smash and grab
    °¡°ÔÀÇ Áö³ç¤©´çÀ» ºÎ¼ö°í °í°¡ÀÇ Áø¿­Ç°À» ¼ø½Ä°£¿¡ »©¾Ñ¾Æ°¡´Â;±×·¯ÇÑ °­µµ;Áø¿­Ã¢ °­µµ
  • tip-and-run
    Àü°ÝÀûÀÎ
  • touch-and-go
    ¾Æ½½¾Æ½½ÇÑ(»óÅÂ)
  • track and field
    À°»ó°æ±â
  • wash-and-wear
    (Á÷¹°ÀÌ) ¼¼Å¹ÈÄ ´Ù¸®Áö ¾Ê°í ÀÔÀ» ¼ö ÀÖ´Â
  • young and all
    ´©±¸³ª ¸ðµÎ;Àü¿ø
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á